Treatment of Severe Recalcitrant Atopic Dermatitis with Dupilumab in a Kidney Transplant Patient

Main Article Content

Vivian Li
Sophie Guenin
Mark Lebwohl


dupilumab, atopic dermatitis, immunosuppressive treatment, transplant


This case report highlights the successful treatment of refractory atopic dermatitis (AD) in an immunosuppressed patient using dupilumab, a biologic agent that selectively targets cytokines crucial in the pathogenesis of AD. The patient had a history of failed treatment with numerous topical and systemic immunomodulating agents, including corticosteroids and immunosuppressive drugs for organ transplant. Dupilumab treatment resulted in significant improvement of symptoms, including reduced pruritus, and ultimately achieved disease control. Importantly, the patient experienced no adverse effects apart from one COVID-19 infection over three years of co-administration of dupilumab with immunosuppressive transplant rejection treatment. The safety of dupilumab in immunocompromised and transplant patients has been a concern, but studies have shown its safety and efficacy in these patient populations. This case highlights the potential for dupilumab as a safe and effective treatment option for patients with severe AD who are immunocompromised or have undergone solid organ transplantation. 



1. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835-852. doi:10.1080/1744666X.2021.1940962

2. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. doi:10.1016/j.jaad.2014.03.030

3. Sidbury R, Kodama S. Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648-652. doi:10.1016/j.clindermatol.2018.05.008

4. Davari DR, Nieman EL, McShane DB, Morrell DS. Current Perspectives on the Systemic Management of Atopic Dermatitis. J Asthma Allergy. 2021;14:595-607. Published 2021 Jun 1. doi:10.2147/JAA.S287638

5. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020

6. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023

7. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs. 2007;67(13):1931-1943. doi:10.2165/00003495-200767130-00012

8. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021;76(4):1053-1076. doi:10.1111/all.14631

9. Lukac D, Pagani K, McGee JS. Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case-series study from a large, urban academic center [published online ahead of print, 2022 Jun 18]. Arch Dermatol Res. 2022;10.1007/s00403-022-02362-y. doi:10.1007/s00403-022-02362-y

10. Fan YH, Lin TL, Sun HL, Pan HH, Ku MS, Lue KH. Successful treatment of atopic dermatitis with dupilumab in the setting of X-linked agammaglobulinemia. J Allergy Clin Immunol Pract. 2022;10(11):3032-3034.e1. doi:10.1016/j.jaip.2022.07.026

11. Wang HJ, Yang TT, Lan CE. Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome. J Eur Acad Dermatol Venereol. 2022;36(5):e367-e369. doi:10.1111/jdv.17889

12. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303. doi:10.1016/S0140-6736(17)31191-1

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>